ArticleBMC health services research2025
Socioeconomic determinants of affordability of medication: a panel data econometric analysis in Iran.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the key aspects of fair access to healthcare is access to affordable medications, which is essential for almost every government. Exploring and estimating the effects of the Social Determinants of Health (SDH) on affordability is an important step to clarify and picture the equity in health and targets for policy making. This paper attempts to estimate these effects on medication affordability in Iran.
methodsWe used data from the Iran Households Survey (IHS) in a 26-year period from 1997 to 2022. We developed a panel data econometric model to estimate the effects of Socioeconomic Determinants (SEDs) on medication expenses and three ratios, including: medication expense/ health costs, income, and all costs, as affordability indices. We employ Fixed Effect (FE) estimators, Random Effect (RE) estimators, Panel Tobit (PT) estimators, and Maximum Likelihood Estimators (MLE) for this purpose.
resultsthe mean medication expenses for each household are about 1.45E + 07 IRR adjusted in 2021(1400 Persian calendar) inflation rate. The Concentration Index (CI) is about 0.12. The median of the medication expenses/ health expenses is about 33.5%. We don’t realize that inequality for this ratio between provinces (CI = -0.01), increase prevalence of rare disease, age of households’ head, increase the share of food and housing expenses, and increase family size can increase household expenses and financial burden. Instead of getting a transfer payment as a cash subsidy, having insurance can reduce medication costs.
conclusionThis study uses provincial panel data to explore socioeconomic determinants of medication affordability, incorporating novel variables like rare disease prevalence, internet access, government support, and pharmacist population. Results show minimal inequality in medication costs among wealthier provinces, with no differences in the medication-to-health expense ratio. Older age, larger household size, and rare disease prevalence hinder affordability, while private insurance and government subsidies improve access. No significant correlations were found between affordability and national insurance or availability. Future research should investigate the causal mechanisms and occupational and educational differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.